“Interest in our Digital Spatial Profiling platform is high, especially among biopharmaceutical researchers. We are excited to be working with innovative CRO partners to reach these potential early adopters through our Technology Access Program,” said
Digital Spatial Profiling
Today, DSP technology can be accessed through the Technology Access Program (TAP) offered through NanoString’s Spatial Genomics Services research laboratory. The TAP announced over a year ago has engaged over 30 customers and has enabled NanoString and its collaborators to highlight the performance of DSP in over ten abstracts presented at major scientific meetings.
The DSP instrument system is currently under development and is expected to be available for early access instrument placements late in 2018 followed by a full commercial launch in 2019.
The DSP instrument is currently intended for research use only and is not for use in diagnostic procedures.
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the performance and attributes of Digital Spatial Profiling, including the commercial availability of DSP and the success of our current efforts through our Technology Access Program to accelerate adoption of DSP by customers following full commercial launch. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in our filings with the
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.